Hepatic inflammatory responses in liver fibrosis
L Hammerich, F Tacke - Nature Reviews Gastroenterology & …, 2023 - nature.com
Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease–novel insights into cellular communication circuits
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Successful development of treatments for non-alcoholic fatty liver disease and its
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …
Treating inflammation to combat non-alcoholic fatty liver disease
L Wiering, F Tacke - Journal of Endocrinology, 2023 - joe.bioscientifica.com
Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …
[HTML][HTML] A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)
S Zhou, H You, S Qiu, D Yu, Y Bai, J He, H Cao… - Biomedicine & …, 2022 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is primarily caused by abnormal lipid metabolism
and the accumulation of triglycerides in the liver. NAFLD is also associated with hepatic …
and the accumulation of triglycerides in the liver. NAFLD is also associated with hepatic …
Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease
S Kamata, A Honda, I Ishii - Biomolecules, 2023 - mdpi.com
The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic
steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the …
steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the …
Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis
T Puengel, S Lefere, J Hundertmark… - International Journal of …, 2022 - mdpi.com
(1) Background: With new potential drug targets emerging, combination therapies appear
attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor …
attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor …
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
EK Wirth, T Puengel, J Spranger… - Expert Review of …, 2022 - Taylor & Francis
Introduction Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic
liver disease worldwide and closely interconnected to the metabolic syndrome. Liver …
liver disease worldwide and closely interconnected to the metabolic syndrome. Liver …
The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer—Challenges and opportunities
MS Kohlhepp, H Liu, F Tacke, A Guillot - Frontiers in molecular …, 2023 - frontiersin.org
Chronic liver diseases from varying etiologies generally lead to liver fibrosis and cirrhosis.
Among them, non-alcoholic fatty liver disease (NAFLD) affects roughly one-quarter of the …
Among them, non-alcoholic fatty liver disease (NAFLD) affects roughly one-quarter of the …
NAFLD and HBV interplay-related mechanisms underlying liver disease progression
E Tourkochristou, SF Assimakopoulos… - Frontiers in …, 2022 - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD) and Hepatitis B virus infection (HBV) constitute
common chronic liver diseases with worldwide distribution. NAFLD burden is expected to …
common chronic liver diseases with worldwide distribution. NAFLD burden is expected to …